InvestorsHub Logo
Post# of 252482
Next 10
Followers 1
Posts 47
Boards Moderated 0
Alias Born 01/21/2003

Re: None

Wednesday, 04/03/2024 11:22:21 AM

Wednesday, April 03, 2024 11:22:21 AM

Post# of 252482
FGEN Fibrogen - why the negative reaction

Hello, would someone please guess as to why the stock is down 40%
I read this press release as fairly positive

Thank you

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer
FG-3246 demonstrated efficacy in adenocarcinoma selected cohorts receiving biologically active doses of FG-3246 at ≥ 1.2 mg/kg in heavily pre-treated, biomarker unselected patients:
Median radiographic progression free survival of 8.7 months
PSA50 response in 36% of patients
Confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months
FG-3246 demonstrated an acceptable safety profile; adverse events consistent with those observed in other antibody drug conjugate therapies with a MMAE payload
Company plans to meet with the U.S. Food and Drug Administration (FDA) to discuss development pathway; Phase 2 initiation is anticipated in 2H 2024
SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload, in a dose-escalation and dose-expansion trial enrolling patients with metastatic castration-resistant prostate cancer (mCRPC) whose tumors have progressed on at least one androgen receptor-signaling inhibitor (ARSI).

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.